10x Genomics delivered strong Q4 2023 results with substantial contributions from Xenium and Visium platforms. As the company enters 2024, its focus on expanding product adoption while managing ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

These capabilities will be available to support both the Chromium and Visium platforms ... tissue organization and function. Xenium RNA+Protein Multiomics: 10x Genomics shared plans to enable ...

10x Genomics stands as a pioneer in the life ... Its key platforms, including Chromium, Visium, and Xenium, allow researchers to explore biological systems with unparalleled detail.

10x Genomics, Inc., a life science technology ... of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve ...

The company also highlighted Visium HD XL, which will feature an expanded capture area to enable whole transcriptome spatial gene expression analysis of larger tissue sections at single-cell-scale ...

The forthcoming Visium HD 3' assay is a reverse transcription ... sections at single-cell-scale resolution. Xenium RNA+Protein Multiomics: 10x Genomics shared plans to enable simultaneous ...